Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor
Brief Summary: This phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia that have come back or have not responded to treatment. T cells that are treated in the laboratory before being given back to the patient may make the body build an immune response to kill cancer cells.


Options:
A: Arm Label: JCAR017 1-dose schedule; Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule | Arm Label: JCAR017 2-dose schedule (no longer accruing); Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) single-dose schedule; Assigned to Arm(s): JCAR017 1-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Assigned to Arm(s): JCAR017 2-dose schedule (no longer accruing)
B: Intervention Type: PROCEDURE; Name: Procedure - Adoptive cell transfer; Assigned to Arm(s): N/A
C: Arm Label: ALL (high tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL (ibrutinib) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL (dose dense) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Intervention Type: BIOLOGICAL; Name: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes; Assigned to Arm(s): ALL (high tumor burden) dose level 1, ALL (high tumor burden) dose level 2, ALL (high tumor burden) dose level 3, ALL (low tumor burden) dose level 1, ALL (low tumor burden) dose level 2, CLL (ibrutinib) dose level 2, CLL dose level 1, CLL dose level 2, CLL dose level 3, NHL (dose dense) dose level 2, NHL dose level 1, NHL dose level 2, NHL dose level 3
D: Arm Label: ACTR087, in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR087, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR087; Assigned to Arm(s): ACTR087, in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR087, in combination with rituximab

Answer: C